Pharmaceuticals, Biotechnology and Life Sciences
NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory…
Carlsbad, CA, Oct. 06, 2025 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) today announced a series of…
– Robust improvement demonstrated across diverse set of clinical measures – – Patient-reported outcomes support clinical meaningfulness of improvements in…
Châtillon, France, October 6, 2025 DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program…
New LEQEMBI Companion™ program launched to expand helpful resources for patients throughout the treatment journey, including Nurse Educators who can provide…
– ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson’s disease – – ARV-102…
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data 50 mg once-daily dose of obefazimod led…
WALTHAM, Mass., Oct. 05, 2025 (GLOBE NEWSWIRE) — Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody…
PHILADELPHIA, Oct. 03, 2025 (GLOBE NEWSWIRE) — Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company…
NEW YORK, Oct. 02, 2025 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory…